Acute Myeloid Leukemia and transplant-eligible disease management
Clinical research activity includes acute myeloid leukemia in older adults being prepared for allogeneic stem cell transplantation, with attention to treatment pathways that support remission and transplant eligibility.
- AML in older patients
- Venetoclax and decitabine
- Allogeneic transplantation readiness
Interest extends to complete remission, complete remission with incomplete count recovery, and morphologic leukemia-free state as clinically relevant states before transplant.
Allogeneic hematopoietic stem cell transplantation support
The sponsor is active in studies centered on allo-HSCT recipients, with a focus on transplant-associated care in patients with acute leukemia and related complications.
- Allogeneic peripheral hematopoietic stem cell transplant
- Neutropenic fever
- Infection risk in transplant recipients
Research activity also addresses the clinical setting of carbapenem-resistant Enterobacteriaceae and Pseudomonas aeruginosa colonization in vulnerable hematology patients.
Cytomegalovirus infection in transplant recipients
Another core area of interest is cytomegalovirus infection in hematopoietic stem cell transplant recipients, especially where standard antiviral options are limited by contraindications or intolerance.
- CMV infection after HSCT
- Maribavir
- Antiviral intolerance
This work reflects attention to post-transplant viral management in patients unable to receive ganciclovir, valganciclovir, or foscarnet.
Severe bacterial infection and antimicrobial support in hematology
Sponsored trials also cover infectious complications in febrile neutropenia and acute leukemia, with emphasis on difficult-to-treat bacterial colonization and the need for intensified antimicrobial support.
- Carbapenem-resistant Enterobacteriaceae
- Pseudomonas aeruginosa
- Febrile acute leukemia
These studies are closely linked to infection control in transplant candidates and patients undergoing intensive hematologic treatment.
